早期肝癌无创诊断之匙——循环游离DNA联合型液体活检

Circulating cell-free DNA-combined liquid biopsy:The key to noninvasive diagnosis of early-stage liver cancer

循环游离DNA(cfDNA)被认为是诊断早期肝癌极具研究前景的液体活检切入点。但不少研究证实单独使用cfDNA作为检测指标其诊断效能缺乏稳定性,尤其是单纯定量分析并不能很好地反映肿瘤情况。而更多研究表示cfDNA适宜多指标联合检测或与其他肝癌诊断标志物进行联合检测。本文回顾了截至2021年7月以cfDNA为出发点的联合型液体活检相关文献,归纳了现有研究中的各联合检测方式,首次就其联合诊断方法的诞生及研究进展进行简要综述,进一步明确cfDNA联合液体活检在诊断早期肝癌中的重要意义与潜力,以期为更好地利用肝癌诊断标志物提供探索思路。

Circulating cell-free DNA(cfDNA)is considered a promising entry point of liquid biopsy for the diagnosis of early-stage liver cancer;however,many studies have confirmed that the diagnostic efficacy of cfDNA alone is not stable,especially that quantitative test alone cannot well reflect the situation of tumor.More and more studies have shown that cfDNA is suitable for combined measurement of multiple indicators or combined measurement with other diagnostic markers for liver cancer.This article reviews the articles on combined liquid biopsy based on cfDNA published up to July 2021,summarizes the existing methods for combined measurement,and briefly describes the birth and research advances in combined diagnostic methods,so as to further clarify the significance and potential of combined liquid biopsy based on cfDNA in the diagnosis of early-stage liver cancer and thus provide ideas for taking better advantages of the diagnostic markers for liver cancer in the future.